Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics SRPT, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SRPT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Sarepta Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 54% leaning bullish and 18% bearish. Among these notable options, 4 are puts, totaling $282,850, and 7 are calls, amounting to $233,830.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $140.0 for Sarepta Therapeutics during the past quarter.
Volume & Open Interest Development
In today's trading context, the average open interest for options of Sarepta Therapeutics stands at 172.62, with a total volume reaching 607.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Sarepta Therapeutics, situated within the strike price corridor from $70.0 to $140.0, throughout the last 30 days.
Sarepta Therapeutics Call and Put Volume: 30-Day Overview
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SRPT | PUT | TRADE | BULLISH | 01/16/26 | $30.9 | $30.3 | $30.3 | $100.00 | $99.9K | 637 | 63 |
| SRPT | PUT | TRADE | BEARISH | 01/16/26 | $30.4 | $29.8 | $30.4 | $100.00 | $72.9K | 637 | 24 |
| SRPT | PUT | TRADE | NEUTRAL | 08/15/25 | $68.2 | $64.2 | $66.16 | $140.00 | $66.1K | 10 | 10 |
| SRPT | PUT | TRADE | BULLISH | 08/15/25 | $24.6 | $24.1 | $24.3 | $95.00 | $43.7K | 142 | 19 |
| SRPT | CALL | TRADE | NEUTRAL | 08/15/25 | $8.9 | $8.4 | $8.65 | $80.00 | $43.2K | 548 | 86 |
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Having examined the options trading patterns of Sarepta Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Present Market Standing of Sarepta Therapeutics
- With a volume of 1,192,820, the price of SRPT is down -0.2% at $73.3.
- RSI indicators hint that the underlying stock may be approaching oversold.
- Next earnings are expected to be released in 40 days.
What The Experts Say On Sarepta Therapeutics
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $141.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * In a cautious move, an analyst from Scotiabank downgraded its rating to Sector Perform, setting a price target of $105. * Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $163. * An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $163. * In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $202. * In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Sell, setting a price target of $75.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Sarepta Therapeutics, Benzinga Pro gives you real-time options trades alerts.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
